Cash Flow Protagonist Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-129.00
279.00
-78.00
-127.00
-128.00
-65.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
146.00
-122.00
-19.00
-7.00
-3.00
-19.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
57.00
184.00
-70.00
-108.00
-107.00
-72.00
Cash Flow from Investing Activities
-49.00
-299.00
-39.00
91.00
-15.00
-90.00
Cash Flow from Financing Activities
22.00
25.00
170.00
18.00
129.00
247.00
Net Cash Inflow / Outflow
31.00
-89.00
60.00
2.00
6.00
84.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Protagonist Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-129.311
-149.344
20.00
13.41%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
146.209
-15.939
161.00
1017.30%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
57.671
-128.336
185.00
144.94%
Cash Flow from Investing Activities
-49.332
134.29
-183.00
-136.74%
Cash Flow from Financing Activities
22.864
-31.697
53.00
172.13%
Net Cash Inflow / Outflow
31.203
-25.743
56.00
221.21%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is -68.68% vs 362.19% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
57.67
184.15
-68.68%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
